A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma

mAbs

Volumn 6, Issue 3, 2014, Pages 756-764

  Cohen, E Suzanne ^a   Dobson, Claire L ^a   Kac̈k, Helena ^b   Wang, Bing ^a   Sims, Dorothy A ^a   Lloyd, Christopher O ^a   England, Elizabeth ^a   Rees, D Gareth ^a   Guo, Hongwei ^b   Karagiannis, Sophia N ^c   O'Brien, Siobhan ^a   Persdotter, Sofia ^b   Ekdahl, Helena ^d   Butler, Robin ^a   Keyes, Feenagh ^a   Oakley, Sarah ^a   Carlsson, Mats ^b   Briend, Emmanuel ^a   Wilkinson, Trevor ^a   Anderson, Ian K ^e   Monk, Phillip D ^f   Wachenfeldt, Karinvon ^g   Eriksson, Per Olof F ^h   Gould, Hannah J ^c   Vaughan, Tristan J ^a   May, Richard D ^a   more..

^a MEDIMMUNE   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Labjoy   (Sweden)

^e JOHNSON AND JOHNSON   (United States)

^f SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^g Truly Translational Sweden AB   (Sweden)

^h Synairgen Research Ltd Southampton General Hospital ^*  (Sweden)

Author keywords

Allergen specific IgE; Anti IgE; Antibody therapeutic; Asthma; IgE; MEDI4212; Monoclonal antibody; Severe asthma

Indexed keywords

ALLERGEN; ANTIASTHMATIC AGENT; CD23 ANTIGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; MEDI 4212; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OMALIZUMAB; UNCLASSIFIED DRUG; ANTI-IGE ANTIBODIES; ANTIGEN ANTIBODY COMPLEX; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PEPTIDE LIBRARY;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; ASTHMA; BINDING AFFINITY; BODY MASS; CRYSTALLOGRAPHY; DRUG EFFICACY; EX VIVO STUDY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; PHAGE DISPLAY; PROTEIN TARGETING; ADOLESCENT; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COHORT ANALYSIS; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PEPTIDE LIBRARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; ANTIGEN-ANTIBODY REACTIONS; ASTHMA; BINDING SITES; COHORT STUDIES; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MIDDLE AGED; MODELS, MOLECULAR; OMALIZUMAB; PEPTIDE LIBRARY; RECEPTORS, IGE; YOUNG ADULT;

EID: 84899708754     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28394     Document Type: Article

References (43)

1. Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006; 100:1139-51; PMID:16713224; http://dx.doi.org/10.1016/j.rmed.2006.03.031
2. Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite L. The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003; 21:579-628; PMID:12500981; http://dx.doi.org/10.1146/annurev. immunol.21.120601.141103
3. Chang TW, Wu PC, Hsu CL, Hung AF. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol 2007; 93:63-119; PMID:17383539; http://dx.doi.org/10.1016/S0065-2776(06)93002-8
4. Wilcock LK, Francis JN, Durham SR. IgE-facilitated antigen presentation: Role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am 2006; 26:333,47, viii-ix.
5. Li H, Nowak-Wegrzyn A, Charlop-Powers Z, Shreffler W, Chehade M, Thomas S, Roda G, Dahan S, Sperber K, Berin MC. Transcytosis of IgE-antigen complexes by CD23a in human intestinal epithelial cells and its role in food allergy. Gastroenterology 2006; 131:47-58; PMID:16831589; http://dx.doi.org/10.1053/j. gastro.2006.03.044
6. Palaniyandi S, Tomei E, Li Z, Conrad DH, Zhu X. CD23-dependent transcytosis of IgE and immune complex across the polarized human respiratory epithelial cells. J Immunol 2011; 186:3484-96; PMID:21307287; http://dx.doi.org/10.4049/jimmunol.1002146
7. Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, et al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007; 179:2832-43; PMID:17709497
8. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59:701-8; PMID:15180756; http://dx.doi.org/10.1111/j.1398-9995.2004.00533.x
9. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-90; PMID:11496232; http://dx.doi.org/10.1067/mai.2001.117880
10. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-61; PMID:11529281; http://dx.doi.org/10.1183/09031936.01.00092101
11. Lanier B. Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. Allergy Asthma Proc 2006; 27(Suppl 1):S37-42; PMID:16722331
12. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101:1483-92; PMID:17339107; http://dx.doi.org/10.1016/j.rmed.2007.01.011
13. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996; 14:309-14; PMID:9630891; http://dx.doi.org/10. 1038/nbt0396-309
14. Lloyd C, Lowe D, Edwards B, Welsh F, Dilks T, Hardman C, Vaughan T. Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel 2009; 22:159-68; PMID:18974080; http://dx.doi.org/10.1093/protein/ gzn058
15. Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992; 224:487-99; PMID:1560463; http://dx.doi.org/10.1016/0022-2836(92)91010-M
16. Bracher M, Gould HJ, Sutton BJ, Dombrowicz D, Karagiannis SN. Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. J Immunol Methods 2007; 323:160-71; PMID:17531261; http://dx.doi.org/10.1016/j.jim.2007.04.009
17. Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature 2000; 406:259-66; PMID:10917520; http://dx.doi.org/10. 1038/35018500
18. Holdom MD, Davies AM, Nettleship JE, Bagby SC, Dhaliwal B, Girardi E, Hunt J, Gould HJ, Beavil AJ, McDonnell JM, et al. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcεRI. Nat Struct Mol Biol 2011; 18:571-6; PMID:21516097; http://dx.doi.org/10.1038/nsmb. 2044
19. Dhaliwal B, Yuan D, Pang MO, Henry AJ, Cain K, Oxbrow A, Fabiane SM, Beavil AJ, McDonnell JM, Gould HJ, et al. Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI. Proc Natl Acad Sci U S A 2012; 109:12686-91; PMID:22802656; http://dx.doi.org/10.1073/pnas.1207278109
20. Demeule B, Shire SJ, Liu J. A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation. Anal Biochem 2009; 388:279-87; PMID:19289095; http://dx.doi.org/10.1016/j.ab.2009.03.012
21. Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19:491-8; PMID:14594521; http://dx.doi.org/10.1185/030079903125002171
22. MacGlashan DW Jr.; W. MD. Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables. J Allergy Clin Immunol 1993; 91:605-15; PMID:7679683; http://dx.doi.org/10.1016/0091- 6749(93)90266-I
23. Corren J, Shapiro G, Reimann J, Deniz Y, Wong D, Adelman D, Togias A. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol 2008; 121:506-11; PMID:18269927; http://dx.doi.org/10.1016/j.jaci.2007.11.026
24. Johansson SG, Nopp A, Oman H, Ankerst J, Cardell LO, Grönneberg R, Matsols H, Rudblad S, Strand V, Stålenheim G. The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. Allergy 2009; 64:1472-7; PMID:19393000; http://dx.doi.org/10.1111/j.1398-9995.2009.02051.x
25. Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy 2009; 64:1780-7; PMID:19627273; http://dx.doi.org/10.1111/j.1398-9995.2009.02119.x
26. Minter RR, Cohen ES, Wang B, Liang M, Vainshtein I, Rees G, et al. Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol 2012; In press; PMID:22913645.
27. Sundberg EJ. 2. structural basis of antibody-antigen interactions. In: Reineke U, Schutkowski M, eds. Epitope Mapping Protocols. 2nd ed.: Humana Press, 2009.
28. Sayers I, Cain SA, Swan JR, Pickett MA, Watt PJ, Holgate ST, Padlan EA, Schuck P, Helm BA. Amino acid residues that influence Fc epsilon RI-mediated effector functions of human immunoglobulin E. Biochemistry 1998; 37:16152-64; PMID:9819207; http://dx.doi.org/10.1021/bi981456k
29. Johansson SG, Oman H, Nopp A, Pettersson S. The importance of IgE antibody levels in anti-IgE treatment. Allergy 2006; 61:1216-9; PMID:16942572; http://dx.doi.org/10.1111/j.1398-9995.2006.01172.x
30. Ankerst J, Nopp A, Johansson SG, Adédoyin J, Oman H. Xolair is effective in allergics with a low serum IgE level. Int Arch Allergy Immunol 2010; 152:71-4; PMID:19940508; http://dx.doi.org/10.1159/000260086
31. Hamilton RG, MacGlashan DW Jr., Saini SS. IgE antibody-specific activity in human allergic disease. Immunol Res 2010; 47:273-84; PMID:20066506; http://dx.doi.org/10.1007/s12026-009-8160-3
32. Bachert C, van Steen K, Zhang N, Holtappels G, Cattaert T, Maus B, et al. Specific IgE against staphylococcus aureus enterotoxins: An independent risk factor for asthma. J Allergy Clin Immunol 2012; 130:376,381 e8.
33. de Llano LP, Vennera MdelC, Álvarez FJ, Medina JF, Borderías L, Pellicer C, González H, Gullón JA, Martínez-Moragón E, Sabadell C, et al.; Spanish Registry. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma 2013; 50:296-301; PMID:23350994; http://dx.doi.org/10.3109/02770903. 2012.757780
34. Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Long-term benefits of omalizumab in a patient with severe nonallergic asthma. Allergy Asthma Clin Immunol 2011; 7:9; PMID:21609447; http://dx.doi.org/10.1186/ 1710-1492-7-9
35. Takhar P, Corrigan CJ, Smurthwaite L, O'Connor BJ, Durham SR, Lee TH, Gould HJ. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol 2007; 119:213-8; PMID:17208604; http://dx.doi.org/10.1016/j.jaci.2006.09.045
36. van den Berge M, Pauw RG, de Monchy JG, van Minnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 2011; 139:190-3; PMID:21208879; http://dx.doi.org/10.1378/chest. 10-0128
37. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009; 68:61-76; PMID:19660004; http://dx.doi.org/10.1111/j.1365-2125.2009.03401.x
38. Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir Med 2013; 107:1141-51; PMID:23721684; http://dx.doi.org/10.1016/ j.rmed.2013.04.017
39. Ikeyama S, Nakagawa S, Arakawa M, Sugino H, Kakinuma A. Purification and characterization of IgE produced by human myeloma cell line, U266. Mol Immunol 1986; 23:159-67; PMID:3702874; http://dx.doi.org/10.1016/0161-5890(86)90038-6
40. Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997; 187:9-18; PMID:9073061; http://dx.doi.org/10.1016/S0378-1119(96)00628-2
41. Rossmann MG. The Molecular Replacement Method. New York: Gordon & Breach, 1972.
42. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63:548-61; PMID:17096680; http://dx.doi.org/10.1111/j. 1365-2125.2006.02803.x
43. Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, Deniz Y, Lowman H, Fielder P, Visich J, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J 2008; 10:425-30; PMID:18686041; http://dx.doi.org/10.1208/s12248-008-9045-4